Nikolaos Vythoulkas-Biotis

Dr. Nikolaos Vythoulkas-Biotis

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Grigorios TsigkasGrigorios Tsigkas
Grigorios Tsigkas
AVAngeliki Vakka
Angeliki Vakka
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
EBEleni Bousoula
Eleni Bousoula
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
PDPeriklis Davlouros
Periklis Davlouros
Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.

Verified
Journal Article
Open access
PDF file
David-Dimitris ChlorogiannisDavid-Dimitris Chlorogiannis
David-Dimitris Chlorogiannis
SPSumant Raghavendra Pargaonkar
Sumant Raghavendra Pargaonkar
Anastasios ApostolosAnastasios Apostolos
Anastasios Apostolos
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
DKDamianos G. Kokkinidis
Damianos G. Kokkinidis
SNSanjana Nagraj
Sanjana Nagraj
As the prevalence of cardiovascular disease continues to increase, early identification of patients at high risk of major adverse cardiovascular events (MACE) using reliable diagnostic modalities is important. Transcatheter aortic valve implantation (TAVI) is a minimally invasive percutaneous procedure used to replace the aortic valve with a bioprosthetic one, often without the need for surgery. Extra coronary calcification in the ascending and/or descending thoracic aorta, aortic arch, and abdominal aorta has recently been identified as a method to quantify the extent of atherosclerotic cardiovascular disease. However, its definitive role in the prediction of MACE remains unclear. We performed a comprehensive review to summarize the current literature on the diagnostic and predictive value of thoracic and abdominal aortic calcification, as quantified in computed tomography, for the association, risk stratification, and prediction of MACE and after TAVI procedures. Despite increasing evidence, the predictive role of thoracic calcification still remains unproven, with a need for carefully tailored studies to confirm these findings.

7 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
Athanasios SamarasAthanasios Samaras
Athanasios Samaras
PTPanagiotis Theofilis
Panagiotis Theofilis
RLRaffaele De Lucia
Raffaele De Lucia
GSGerasimos Siasos
Gerasimos Siasos
Atrial fibrillation (AF) is a highly prevalent arrhythmia associated with stroke, heart failure and excess mortality. Yet, “silent” AF episodes remain undetected, leading to underestimation of disease burden. Additionally, paroxysms occur in an “unpredictable” way, and available clinical scores only stratify long-term AF risk with moderate discrimination, lacking the ability to evaluate near-term events. Artificial intelligence (AI) applied to sinus rhythm from short or continuous electrocardiogram (ECG) recordings shows that such predictive information is hidden in “plain sight.” This complementary approach seeks to uncover latent AF substrate and forecast imminent AF episodes. Deep-learning models trained on 10-s, 12-lead ECGs can identify individuals with prevalent or long- or near-term AF with areas under the curve (AUCs) up to 0.90, outperforming established clinical scores. Image-based AI-ECG models extend these capabilities to paper or scanned ECGs. Furthermore, AI algorithms applied to 24-h Holter and multi-day patch recordings achieve AUCs ≥0.80 for detecting occult AF or predicting it within 14 days, consistently surpassing risk scores like C2HEST and HATCH. Short-term models utilizing heart-rate variability features further demonstrate that AF can be anticipated minutes to hours before onset, with accuracies around 90% in curated datasets. However, most AI-AF studies remain retrospective, single-system and focused on diagnostic yield rather than clinical outcomes like stroke or mortality. Moreover, few pragmatic trials have evaluated AI-guided AF screening and its translation into clinical benefit. Robust prospective trials and standardized evaluation frameworks are needed before AI-guided AF prediction can be routinely integrated into clinical decision-making.

16 August 2023 in JACC: Case Reports
Verified
Journal Article
Open access
KKKonstantinos Kalogeras
Konstantinos Kalogeras
SKStella-Maria Kyvelou
Stella-Maria Kyvelou
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
TPTheodoros Pesiridis
Theodoros Pesiridis
GVGeorgia Vogiatzi
Georgia Vogiatzi
MVManolis Vavuranakis
Manolis Vavuranakis
Patients with inherited hypercoagulopathies such as protein-S deficiency commonly present with venous thrombosis. However, there are rare cases of arterial thrombosis. We describe a rare case of a diffuse left anterior descending and left ventricular thrombus in a young patient with protein-S deficiency complicated with mid cerebral artery occlusion. (Level of Difficulty: Intermediate.)

23 September 2025 in IJC Heart & Vasculature
Verified
Journal Article
Open access
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
DCDavid-Dimitris Chlorogiannis
David-Dimitris Chlorogiannis
TTTheoni Theodoropoulou
Theoni Theodoropoulou
IGIoannis Gialamas
Ioannis Gialamas
EOEvangelos Oikonomou
Evangelos Oikonomou
MVManolis Vavuranakis
Manolis Vavuranakis
Percutaneous coronary intervention (PCI) in patients with active or prior history of cancer presents a challenge due to the increased rates of cardiovascular complications. Therefore, we aimed to evaluate the mortality rates, in addition to early and long-term adverse cardiovascular outcomes in this high-risk population. A systematic literature search was conducted across PubMed, Cochrane, and Scopus databases to identify eligible studies comparing clinical outcomes between patients with active or prior history of cancer and patients without cancer. Our primary outcomes were all-cause mortality and cardiovascular mortality at different time points. Secondary outcomes included bleeding, stroke, recurrent myocardial infarction (MI), and heart failure events between the two groups. Overall, 18 studies with a total of 8 million patients were included. Active or prior history of cancer was associated with increased in-hospital all-cause mortality (RR: 1.43; 95 % CI: 1.03–1.99; p = 0.03), 1-year all-cause mortality (RR: 2.35; 95 % CI: 1.75–3.16; p < 0.001), as well as, increased 1-year cardiovascular mortality (RR: 1.35; 95 % CI: 1.15–1.59; p < 0.001) compared to patients without a history of cancer. Patients with active or prior history of cancer have higher rates of in-hospital (RR: 1.77; 95 % CI: 1.75–1.79; p < 0.001), 1-year (RR: 1.63; 95 %CI: 1.26–2.11; p < 0.001), and long-term bleeding events (RR: 2.08; 95 % CI: 1.30–3.35; p < 0.003) compared to patients without cancer. No significant differences were recorded regarding recurrent MI between the two groups. Active or prior history of cancer was associated with a negative impact on early and long-term clinical outcomes in patients undergoing PCI. These findings underline the importance of individualized and multidisciplinary approaches when treating this high-risk population.

25 February 2026 in Angiology
Verified
Journal Article
Closed access
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
TTTheoni Theodoropoulou
Theoni Theodoropoulou
IGIoannis Gialamas
Ioannis Gialamas
ALAntonios Lysandrou
Antonios Lysandrou
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
KKKonstantinos Kalogeras
Konstantinos Kalogeras
Complications related to vascular closure devices (VCDs) remain relatively common after transcatheter aortic valve implantation (TAVI), while the optimal suture-based strategy remains a subject of debate. This systematic review and meta-analysis aim to evaluate the efficacy and safety of single versus double Perclose VCD in patients undergoing transfemoral TAVI. A literature search was conducted across PubMed, Scopus, and Cochrane databases to identify appropriate studies. The primary outcome was technical success; secondary outcomes included vascular and bleeding complications, bailout interventions, and all-cause mortality. Seven studies (3940 patients) fulfilled the inclusion criteria. Technical success was comparable between the two strategies (relative risk [RR]: .89; 95% confidence interval [CI]: .64-1.22), while the single Perclose strategy was associated with a lower risk of major vascular complications (RR: .61; 95% CI: .40-.92), major bleeding (RR: .28; 95% CI: .11-.73) and bailout surgical interventions (RR: .45; 95% CI: .24-.84). There were no differences in minor vascular complications and all-cause mortality. Stepwise closure with the upfront single Perclose strategy demonstrated comparable technical success and a more favorable safety profile regarding major vascular complications and bleeding compared with the double Perclose strategy. Additional randomized controlled trials are essential to validate these findings.